Standard pre‑examination protocol – must be demonstrated:
Action: Introduce yourself, explain the examination, and obtain verbal consent.
Key observations:
Anthropometry:
Systematic examination:
Assess:
📋 Case Presentation – (fill in during exam)
This is a _____-year-old _____ child, referred for _____ (early breast development / testicular enlargement / pubic hair / growth spurt). On examination, the child appears _____ (well/unwell/lethargic), with _____ (body habitus / dysmorphic features). Measurements: height _____ percentile, bone age _____ (advanced/delayed), weight _____ percentile. Tanner staging: breasts _____, pubic hair _____, testes (boys) _____ mL. General exam: _____ (skin, eyes, neck, abdomen, genitalia). Developmental: _____ (advanced/appropriate/delayed). Associated signs: _____.
Central (GnRH‑dependent) Precocious Puberty
• Idiopathic (most common in girls)
• CNS tumours (hypothalamic hamartoma, optic glioma, craniopharyngioma)
• CNS irradiation, trauma, infection
• Neurofibromatosis type 1 (optic glioma)
Peripheral (GnRH‑independent) Precocious Puberty
• McCune‑Albright syndrome
• Congenital adrenal hyperplasia (21‑hydroxylase, 11β‑hydroxylase)
• Gonadal tumours (ovarian – granulosa cell; testicular – Leydig cell)
• hCG‑secreting tumours (hepatoblastoma, germinoma)
• Exogenous sex steroids (ingestion, creams)
• Primary hypothyroidism (Van Wyk‑Grumbach – rare)
Variants (not true precocious puberty)
• Premature thelarche (isolated breast development)
• Premature adrenarche (isolated pubic hair)
• Premature menarche
• Bone age – advanced (true precocious puberty).
• GnRH stimulation test – pubertal LH response (central) vs prepubertal (peripheral).
• Basal LH, FSH, oestradiol (girls), testosterone (boys) – elevated in central puberty.
• 17‑OHP, androstenedione, DHEAS – elevated in CAH.
• hCG – elevated in hCG‑secreting tumours.
• Thyroid function – to exclude hypothyroidism.
• MRI brain – to identify CNS lesions (hamartoma, tumour).
• Pelvic ultrasound – ovarian cysts/tumours (girls).
• Testicular ultrasound – Leydig cell tumours (boys).
• Abdominal ultrasound – hepatoblastoma, adrenal mass.
• Skeletal survey – fibrous dysplasia (McCune‑Albright).
• Genetic – FISH (NF‑1), GNAS (McCune‑Albright), CYP21A2 (CAH).
• GnRH stimulation test – differentiate central vs peripheral.
• 17‑OHP – exclude CAH.
• Thyroid function – exclude hypothyroidism.
• hCG – exclude hCG‑secreting tumours.
• Imaging – to exclude tumours (CNS, gonadal, adrenal).
• Ophthalmology – visual fields (if CNS lesion).
• Neurology – if CNS lesion.
• Cardiac – if McCune‑Albright (cardiac involvement rare).
• Psychosocial – assess impact on child & family.
🔹 Management – Across Organ Systems
GnRH analogues (leuprolide, triptorelin) – arrest puberty, preserve adult height.
Aromatase inhibitors (letrozole, anastrozole); tamoxifen.
Glucocorticoid (hydrocortisone) + mineralocorticoid (fludrocortisone) replacement.
Surgical excision (gonadal, adrenal, hepatoblastoma).
Thyroxine replacement.
Remove source of sex steroids.
Counselling, support for child and family (early puberty can cause bullying, emotional issues).
Monitor growth, bone age, hormone levels; regular imaging if tumour.
📈 Prognosis
📋 Follow‑up Schedule